Investor Presentaiton
Investor presentation
ADA 2019
Slide 12
Progress on several projects since ADA last year
June 2018 A
A
June 2019
Bridging
strategy for
semaglutide
CV labels
PIONEER
2, 3, 4 and
7 results
STEP
obesity
phase 3
initiated
PIONEER
5, 8 and 10
results
Ziylo acquisition
for accelerating
glucose
responsive
insulin
PIONEER 9
and 6
results
DUAL VIII
completed for
XultophyⓇ
US filing of oral
semaglutide and
CV label for
Ozempic® and
oral semaglutide
AM833
phase 2
initiated
OG2023
phase 1
initiated
SELECT
obesity
CVOT phase
3 initiated
REFLECT
RWE trial
completed
for Tresiba®
LAI287
phase 2
initiated
EU and CA
filings of oral
semaglutide
GLP-1
Insulin
Obesity
& NASH
Real-World
Evidence
Regulatory
Partnership
with Gilead
Science
announced
novo nordiskView entire presentation